Wei-xiang Qi

Featured in: Favicon

biomedcentral.com Favicon

futuremedicine.com Favicon

thebreastonline.com Favicon

onlinelibrary.wiley.com Favicon

bmccancer.biomedcentral.com

Articles

A randomized trial of early cardiotoxicity in breast cancer patients receiving postoperative IMRT with or without serial cardiac dose constraints

Nov 5, 2024 | onlinelibrary.wiley.com | Lu Cao |Dan Ou |Wei-xiang Qi |Cheng Xu

1 INTRODUCTION Postoperative radiotherapy (RT) plays an indispensable role in reducing recurrence and improving survival in breast cancer (BC) patients.1, 2 However, evidence has shown that radiation-induced heart disease (RIHD) would offset the survival benefits at different extents.3, 4 Unlike systemic treatments that are administered with fixed doses, radiation dose to the heart depends on predefined constraints and techniques.
The addition of pembrolizumab to neoadjuvant chemoradiotherapy did not increase the risk of developing postoperative anastomotic leakage for ESCC: an analysis from a prospective cohort | BMC Cancer | Full Text

Aug 20, 2024 | bmccancer.biomedcentral.com | Wei-xiang Qi |Shuyan Li |Huan Li |Jiayi Chen |Shengguang Zhao

The study was designed as a prospective cohort from four prospective trials (NCT NCT04435197, NCT04435197, NCT04513418, NCT03990532) [24,25,26], and all included patients were treated with NCRT with or without pembrolizumab followed by esophagectomy and reconstructed the conduit with a narrow gastric tube intrathoracic or cervical anastomosis at Ruijin Hospital, Shanghai Jiao Tong university school of medicine, between Jan 2019 and July 2023.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →